



## Kubota Vision Presents at the Australian Space Biology x Health Symposium

Seattle (November 21, 2021) — Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that Dr. Ryo Kubota, Chairman, President and CEO of Kubota Vision Inc., presented on one of the company's leading development programs, home-based OCT (optical coherence tomography) retinal monitoring system, at the [Australian Space Biology x Health Symposium \(ASBX\) 2021](#) during the Humans Physiology in Space session on November 16, 2021.

The information about the presentation is as follows:

**Title:** "Use of compact OCT for long duration space mission to monitor SANS"

**URL:** <https://www.youtube.com/watch?v=B9EvFUNiMZE>

The Australian Space Biology Symposium (ASBS) was first established in 2019 with the vision of bringing together the international research and industry community in order to bridge the gap between basic science and technology for humans in space. After another successful symposium in 2020, this year's ASBX provided a venue to think further about the big questions of humanity and space by inviting international experts for innovative and yet problem-solving possibilities in the space STEM arena.

Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., stated, "It is a great honor and pleasure to speak at the ASBX, where like-minded individuals can come together and share all the advances that have been made in space innovation and technologies. We started a project in 2019 to develop a compact OCT device for NASA's Deep Space missions and are continuously discussing the details of Phase 2 of this project with them, even with the challenges the pandemic has caused. Our mission is to demonstrate the technologies and accelerate our business to the next level."

### About Kubota Vision Inc.

Kubota Vision Inc. is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Kubota Pharmaceutical group's development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt disease. The company is also developing a handheld OCT device for the monitoring of neovascular retinal diseases, to be used directly by patients, and wearable device for myopia control. <https://www.kubotavision.com/>; <https://www.kubotaholdings.co.jp/en/>

### Cautionary Statements

Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include statements regarding our expectations related to our development plans and ability to

successfully develop and commercialize our product candidates and the potential efficacy, future development plans and commercial potential of our product candidates. These statements are based on current assumptions that involve risks, uncertainties and other factors that could cause the actual results, events or developments to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our investigational product candidates may not demonstrate the expected safety and efficacy; our pre-clinical development efforts may not yield additional product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; our clinical trials could be delayed; new developments in the intensely competitive ophthalmic pharmaceutical market may require changes in our clinical trial plans or limit the potential benefits of our investigational product candidates; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. For a detailed discussion of the foregoing risks and other risk factors, please refer to our filings with the Securities and Exchange Commission, which are available on Kubota Pharmaceutical Holdings (Kubota Vision's parent company) investor relations website (<https://www.kubotaholdings.co.jp/en/ir/>) and on the SEC's website (<http://www.sec.gov>).

“Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

**Media and Investor Relations Contact:**

Press and Media Inquiries

Phone: +81-3-6550-8928

Email: [pr@kubotaholdings.co.jp](mailto:pr@kubotaholdings.co.jp)

###